CLINICAL_TRIALS
trial_result
· 2016-06-13
Clinical Trial Update: Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS) [Phase 1, Phase 2]
Summary
This entry notes the completion of Phase 1 and Phase 2 studies of TU-100 (Daikenchuto) in patients with irritable bowel syndrome.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tsumura USA | Conditions: Irritable Bowel Syndrome, Digestive System Diseases | Phase 1, Phase 2 | Status: COMPLETED